S1PR1 and systemic lupus erythematosus: S1P1‐desensitizing molecules in clinical development include ponesimod (in phase 3 trials for MS) as well as molecules that have shown efficacy in other autoimmune diseases including inflammatory bowel disease, lupus, and psoriasis [6, 7, 8].